Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina (RENEW)

This study has been completed.
Information provided by (Responsible Party):
Baxalta US Inc.
ClinicalTrials.gov Identifier:
First received: January 10, 2012
Last updated: November 22, 2016
Last verified: November 2016